4//SEC Filing
Gullans Steven R. Ph.D. 4
Accession 0001596771-18-000019
CIK 0001638287other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:31 PM ET
Size
5.2 KB
Accession
0001596771-18-000019
Insider Transaction Report
Form 4
Gullans Steven R. Ph.D.
Director
Transactions
- Purchase
Common Stock
2018-02-08$7.00/sh+71,429$500,003→ 930,252 total(indirect: Held by Excel Venture Fund II, L.P.)
Footnotes (2)
- [F1]The shares were purchased in a confidentially marketed public offering pursuant to an Underwriting Agreement. The offering closed on February 12, 2018.
- [F2]The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Documents
Issuer
Gemphire Therapeutics Inc.
CIK 0001638287
Entity typeother
Related Parties
1- filerCIK 0001571997
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 4:31 PM ET
- Size
- 5.2 KB